ISSN 2149-2263 | E-ISSN 2149-2271
The Anatolian Journal of Cardiology
Structural and Functional Impact of Adrenoceptor Beta-1 Gene Polymorphism in Patients with Hypertrophic Cardiomyopathy and Response to Beta-Blocker Therapy [Anatol J Cardiol]
Anatol J Cardiol. 2024; 28(3): 150-157 | DOI: 10.14744/AnatolJCardiol.2023.3898

Structural and Functional Impact of Adrenoceptor Beta-1 Gene Polymorphism in Patients with Hypertrophic Cardiomyopathy and Response to Beta-Blocker Therapy

Damla Raimoglou1, Cemil İzgi2, Rasim Enar1, M. Hakan Karpuz1, Bilgehan Karadağ1, Barış İktimur1, Utku Raimoğlu1, Ali Uğur Soysal1, Osman Aykan Kargın3, Mehmet Güven4, Namina Malikova4, Elif Çıtak4, Ece Yurtseven5, Eser Durmaz1
1Department of Cardiology, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye
2Department of Cardiology, Royal Brompton and Harefield Hospitals, London, United Kingdom
3Department of Radiology, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye
4Department of Medical Biology, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye
5Department of Cardiology, Koç University Faculty of Medicine, İstanbul, Türkiye

Background: Hypertrophic cardiomyopathy (HCM) is a genetically inherited cardiac disorder with diverse clinical presentations. Adrenergic activity, primarily mediated through beta-adrenoceptors, plays a central role in the clinical course of HCM. Adrenergic stimulation increases cardiac contractility and heart rate through beta-1 adrenoceptor activation. Beta-blocker drugs are recommended as the primary treatment for symptomatic HCM patients to mitigate these effects.

Methods: This prospective study aimed to investigate the impact of common ADRB-1 gene polymorphisms, specifically serine–glycine at position 49 and arginine–glycine at position 389, on the clinical and structural aspects of HCM. Additionally, the study explored the association between these genetic variations and the response to beta-blocker therapy in HCM patients.

Results: A cohort of 147 HCM patients was enrolled, and comprehensive assessments were performed. The findings revealed that the Ser49Gly polymorphism significantly influenced ventricular ectopic beats, with beta-blocker therapy effectively reducing them in Ser49 homozygous patients. Moreover, natriuretic peptide levels decreased, particularly in Ser49 homozygotes, indicating improved cardiac function. Left ventricular outflow obstruction, a hallmark of HCM, was also reduced following beta-blocker treatment in all patient groups. In contrast, the Arg389Gly polymorphism did not significantly impact baseline parameters or beta-blocker response.

Conclusion: These results emphasize the role of the Ser49Gly polymorphism in the ADRB-1 gene in shaping the clinical course and response to beta-blocker therapy in HCM patients. This insight may enable a more personalized approach to managing HCM by considering genetic factors in treatment decisions. Further research with larger populations and longer follow-up periods is needed to confirm and expand upon these findings.

Keywords: Adrenoceptor-1 gene polymorphism, genetics, hypertrophic cardiomyopathy

Damla Raimoglou, Cemil İzgi, Rasim Enar, M. Hakan Karpuz, Bilgehan Karadağ, Barış İktimur, Utku Raimoğlu, Ali Uğur Soysal, Osman Aykan Kargın, Mehmet Güven, Namina Malikova, Elif Çıtak, Ece Yurtseven, Eser Durmaz. Structural and Functional Impact of Adrenoceptor Beta-1 Gene Polymorphism in Patients with Hypertrophic Cardiomyopathy and Response to Beta-Blocker Therapy. Anatol J Cardiol. 2024; 28(3): 150-157

Corresponding Author: Damla Raimoglou
Manuscript Language: English


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search

Copyright © 2024 The Anatolian Journal of Cardiology



Kare Publishing is a subsidiary of Kare Media.